Reported Earnings • May 23
Full year 2026 earnings released: ₹1.98 loss per share (vs ₹0.94 profit in FY 2025) Full year 2026 results: ₹1.98 loss per share (down from ₹0.94 profit in FY 2025). Revenue: ₹2.84b (up 1.5% from FY 2025). Net loss: ₹109.3m (down 317% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. New Risk • May 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m). New Risk • Feb 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m). Reported Earnings • Jan 30
Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025) Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Ankündigung • Jan 22
Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026 Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026 Reported Earnings • Oct 19
Second quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.77 in 2Q 2025) Second quarter 2026 results: EPS: ₹1.43 (up from ₹0.77 in 2Q 2025). Revenue: ₹879.0m (up 20% from 2Q 2025). Net income: ₹79.1m (up 91% from 2Q 2025). Profit margin: 9.0% (up from 5.6% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Ankündigung • Sep 01
Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025 Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 08
First quarter 2026 earnings released: ₹1.00 loss per share (vs ₹0.75 profit in 1Q 2025) First quarter 2026 results: ₹1.00 loss per share (down from ₹0.75 profit in 1Q 2025). Revenue: ₹629.8m (down 10% from 1Q 2025). Net loss: ₹55.1m (down 237% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Ankündigung • Aug 02
Quick Heal Technologies Limited to Report Q1, 2026 Results on Aug 07, 2025 Quick Heal Technologies Limited announced that they will report Q1, 2026 results on Aug 07, 2025 New Risk • Jun 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.8% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin). Reported Earnings • May 10
Full year 2025 earnings released: EPS: ₹0.94 (vs ₹4.56 in FY 2024) Full year 2025 results: EPS: ₹0.94 (down from ₹4.56 in FY 2024). Revenue: ₹3.00b (up 2.9% from FY 2024). Net income: ₹50.4m (down 79% from FY 2024). Profit margin: 1.7% (down from 8.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Ankündigung • May 01
Quick Heal Technologies Limited to Report Q4, 2025 Results on May 06, 2025 Quick Heal Technologies Limited announced that they will report Q4, 2025 results on May 06, 2025 Ankündigung • Apr 01
Quick Heal Technologies Limited Announces Resignation of Shailesh Lakhani as Director Quick Heal Technologies Limited announced resignation of Mr. Shailesh Lakhani as Director with effect from 31 March 2025. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹297, the stock trades at a trailing P/E ratio of 71.5x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 74% over the past three years. Reported Earnings • Feb 05
Third quarter 2025 earnings released: EPS: ₹0.02 (vs ₹1.89 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.02 (down from ₹1.89 in 3Q 2024). Revenue: ₹755.2m (down 7.8% from 3Q 2024). Net income: ₹1.10m (down 99% from 3Q 2024). Profit margin: 0.1% (down from 12% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Ankündigung • Jan 29
Quick Heal Technologies Limited to Report Q3, 2025 Results on Feb 04, 2025 Quick Heal Technologies Limited announced that they will report Q3, 2025 results at 12:08 PM, Indian Standard Time on Feb 04, 2025 Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹469, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 37x in the Software industry in India. Total returns to shareholders of 135% over the past three years. Ankündigung • Dec 04
Quick Heal Technologies Limited Launches Seqrite Malware Analysis Platform and Threat Intel Solution Quick Heal Technologies Limited announced that the company announce the launch of its new product on 4 December, 2024 and issue of India Cyber Threat Report 2025. The product named Seqrite Malware Analysis Platform (SMAP) and Threat Intel Solution is set to launch on 4 December 2024. It falls under the category of Enterprise Security Software, specifically designed as a Malware Analysis Platform and Threat Intel Solution. This product will cater to the domestic market initially, with the first phase being introduced in the Domestic Market and plans to subsequently expand into other geographies. New Risk • Nov 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹19m sold). Reported Earnings • Oct 18
Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹2.43 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.77 (down from ₹2.43 in 2Q 2024). Revenue: ₹786.9m (flat on 2Q 2024). Net income: ₹41.5m (down 68% from 2Q 2024). Profit margin: 5.3% (down from 17% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings. Ankündigung • Oct 11
Quick Heal Technologies Limited to Report Q2, 2025 Results on Oct 17, 2024 Quick Heal Technologies Limited announced that they will report Q2, 2025 results on Oct 17, 2024 Ankündigung • Oct 04
Quick Heal Technologies Limited Announces the Launch of India's First Fraud Prevention Solution - AntiFraud.AI Quick Heal Technologies Limited announced the launch of India's first fraud prevention solution - AntiFraud.AI. This 'Made in India' solution opens a whole new category revolutionizing digital safety against the escalating threat of financial frauds which is impacting everyone including the most tech-savvy. The launch of AntiFraud.AI comes at a crucial time when financial fraud has reached alarming levels. According to the Indian Cybercrime Coordination Centre, the approximate amount that Indians lost to fraudsters between January to April 2024 stood at 1750 crores. The gravity of the situation is further underlined by the National Cybercrime Reporting Portal, suffered losses were reported through over 740,000 complaints. These staggering figures highlight the urgent need for comprehensive fraud prevention solutions, a need that Quick Heal's AntiFraud.AI aims to address head-on. AntiFraud.AI boasts a wide range of robust features designed to enhance user security and safeguard sensitive information. Key Features Include: 1. Risk Profile - Assess risk level with actionable recommendations to reduce exposure to fraud. 2. Fraud Call Alert - Alerts on receiving a potentially fraudulent call. 3. Scam Protection - Employs sophisticated algorithms to identify and block phishing links and fraudulent websites, enhancing online security. 4. Banking Fraud Alert - Utilizes artificial intelligence to detect and alert users to potential banking fraud attempts in real-time. 5. Fraud Protect Buddy - Empowers users to safeguard their loved ones by sharing alerts and security tips, specifically addressing the vulnerabilities of less tech-savvy individuals. 6. Fraud App Detector - Continuously scans for malicious applications and delivers real-time alerts about potentially harmful apps. 7. Secure Payments - Ensures a safe environment for online transactions and monitors for suspicious activity throughout the payment process. Unauthorized Access Alert - Notifies users if their device's microphone or camera is activated without consent, protecting against covert surveillance. Dark Web Monitoring - Actively scans the dark web for compromised sensitive data and provides timely notifications if users' information is found. . Call Forwarding Alert - Alerts when calls are being redirected without consent, The solution also offers Screen share alert, Payee Name Announcer, Spy Alert, File Vault and Browsing Protection and more. In addition to these, The Information Hub feature provides access to in-depth research and fraud intelligence from Seqrite Labs, India's largest malware analysis facility, keeping users informed about evolving threats with the latest fraud trends and prevention tips. This feature allows users to access Quick Heal's extensive domain expertise and knowledge. Furthermore, the Victim Support feature offers step- by-step guidance for those who fall victim to fraud, aiding in recovery and necessary actions. Together, these elements create a robust defense against fraud and enhance overall digital security. Board Change • Oct 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Kamal Agarwal was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 09
Quick Heal Technologies Limited Appoints Kamal Kumar Agarwal as an Independent Director Quick Heal Technologies Limited approved the appointment of Mr. Kamal Kumar Agarwal as an Independent Director of the company for a first term of five years commencing from July 26, 2024 at the AGM held on September 06, 2024. Mr. Kamal Kumar Agarwal 43, is a graduate in Bachelor of Commerce in year 2001. He is a Member of the Institute of Chartered Accountants of India. Part of CFO 100 2013 and 2016 Honor list under 'Winning Edge in a Finance Start-up. Mr. Kamal Kumar Agarwal, serving /served as Non-Executive Director & Investor Advisor for M/s NewCold, MN Bio-Technology, Giant Connection & a few. Mr. Kamal Kumar Agarwal has served as Group CFO - Indian
Subcontinent & Director at Ferrero India Private Limited. He was also worked with blue chip companies Cadbury India Private Limited, ITC Limited and Tata Teleservices
Limited. Currently incubating two additional ventures since Fiscal Year 22/23 Hampa Wellness (a hemp-based product co.) and Peaceful Progress LLP (Cat 1 SEBI approved AIF 20 investments till date). In the past, have built and sold - Winter Logistics to M/s Dubai Port. Management Buy Out (by-self), and Multi Million Dollars PE-funding (Goldman Sachs and Mitsui) of The Good Stuff Private Limited a venture focused on FMCG that has seen Sell Out to M/s DS Group. Mr. Kamal Kumar Agarwal is not related to any director of the
company. Upcoming Dividend • Aug 23
Upcoming dividend of ₹3.00 per share Eligible shareholders must have bought the stock before 30 August 2024. Payment date: 06 October 2024. Payout ratio is a comfortable 66% but the company is paying out more than the cash it is generating. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (1.2%). Ankündigung • Aug 16
Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024 Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024, at 16:00 Indian Standard Time. Reported Earnings • Jul 27
First quarter 2025 earnings released: EPS: ₹0.75 (vs ₹2.40 loss in 1Q 2024) First quarter 2025 results: EPS: ₹0.75 (up from ₹2.40 loss in 1Q 2024). Revenue: ₹753.5m (up 47% from 1Q 2024). Net income: ₹40.3m (up ₹167.9m from 1Q 2024). Profit margin: 5.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Ankündigung • Jul 18
Quick Heal Technologies Limited to Report Q1, 2025 Results on Jul 26, 2024 Quick Heal Technologies Limited announced that they will report Q1, 2025 results on Jul 26, 2024 Reported Earnings • Apr 26
Full year 2024 earnings released: EPS: ₹4.56 (vs ₹1.14 in FY 2023) Full year 2024 results: EPS: ₹4.56 (up from ₹1.14 in FY 2023). Revenue: ₹3.13b (up 13% from FY 2023). Net income: ₹242.4m (up 279% from FY 2023). Profit margin: 7.7% (up from 2.3% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. Ankündigung • Apr 26
Quick Heal Technologies Limited Recommends Final Dividend for the Year 2023-24 Quick Heal Technologies Limited has recommended a final dividend of 3 per equity share of 10/- each for the year 2023-24 subject to approval of shareholders in ensuing AGM. Ankündigung • Apr 19
Quick Heal Technologies Limited to Report Q4, 2024 Results on Apr 25, 2024 Quick Heal Technologies Limited announced that they will report Q4, 2024 results at 4:00 PM, Indian Standard Time on Apr 25, 2024 Recent Insider Transactions • Mar 12
Head of Retail Sales recently sold ₹1.1m worth of stock On the 4th of March, Deepak Mishra sold around 2k shares on-market at roughly ₹565 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹41m more than they bought in the last 12 months. Recent Insider Transactions • Mar 06
Head of Retail Sales recently sold ₹3.5m worth of stock On the 1st of March, Deepak Mishra sold around 6k shares on-market at roughly ₹545 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹40m more than they bought in the last 12 months. Ankündigung • Jan 25
Quick Heal Technologies Limited Announces Appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product Officer Quick Heal Technologies Limited announced the appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product Officer, effective from January 24, 2024. Dr. Lalit is PHD in Computer Science and Bachelor of Engineering from IIT Hyderabad in Threat Intelligence. He has experience of over 25 year in IT and Cyber Security Industry. Reported Earnings • Jan 25
Third quarter 2024 earnings released: EPS: ₹1.89 (vs ₹1.70 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹1.89 (up from ₹1.70 loss in 3Q 2023). Revenue: ₹860.7m (up 29% from 3Q 2023). Net income: ₹100.6m (up ₹193.5m from 3Q 2023). Profit margin: 12% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Ankündigung • Jan 11
Quick Heal Technologies Limited to Report Q2, 2024 Results on Jan 24, 2024 Quick Heal Technologies Limited announced that they will report Q2, 2024 results on Jan 24, 2024 Recent Insider Transactions • Dec 20
Chief Product Officer recently sold ₹29m worth of stock On the 15th of December, Sanjay Agrawal sold around 77k shares on-market at roughly ₹369 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Oct 29
Second quarter 2024 earnings released: EPS: ₹2.43 (vs ₹3.82 in 2Q 2023) Second quarter 2024 results: EPS: ₹2.43 (down from ₹3.82 in 2Q 2023). Revenue: ₹840.5m (down 17% from 2Q 2023). Net income: ₹129.0m (down 42% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Ankündigung • Oct 28
Quick Heal Technologies Limited Appoints Sarang Deshpande as Company Secretary and Compliance Officer Quick Heal Technologies Limited announced the appointment of Mr. Sarang Deshpande as company Secretary and Compliance Officer. Date of appointment is 26 October, 2023. Mr. Sarang Deshpande is a member of Institute of Company Secretaries of India (ICSI). He is a Bachelor of Legislative Law (LL.B.) and Master of Commerce (M.Com) having more than 18 years of experience in the field of secretarial, legal and compliance of listed and unlisted companies. Ankündigung • Sep 13
Quick Heal Technologies Limited Announces the Resignation of Vinav Agarwal as Compliance Officer, Effective September 15, 2023 Quick Heal Technologies Limited announced the resignation of Mr. Vinav Agarwal as Compliance Officer, due to personal reasons. Date of cessation is September 15, 2023. Board Change • Sep 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Richard Stiennon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Share price has been volatile over the past 3 months (7.3% average weekly change). Ankündigung • Jul 22
Quick Heal Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023 Quick Heal Technologies Limited at its Annual General Meeting to be held on August 11, 2023, proposed to declare a final dividend of INR 2.50 per equity share of face value INR 10 each for the financial year ended March 31, 2023. New Risk • Jul 22
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.08b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Market cap is less than US$100m (₹8.08b market cap, or US$98.5m). Reported Earnings • Jul 21
First quarter 2024 earnings released: ₹2.40 loss per share (vs ₹0.03 profit in 1Q 2023) First quarter 2024 results: ₹2.40 loss per share (down from ₹0.03 profit in 1Q 2023). Revenue: ₹561.7m (down 8.0% from 1Q 2023). Net loss: ₹127.6m (down ₹129.4m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Ankündigung • Jul 18
Quick Heal Technologies Limited Announces Resignation of Srinivasa Rao as Company Secretary & Key Managerial Person Quick Heal Technologies Limited announced that Mr. A. Srinivasa Rao, has given the resignation from the post of Company Secretary & Key Managerial Person (KMP) of Company vide his resignation letter as received on July 17, 2023 due to personal reasons. Ankündigung • Jul 15
Quick Heal Technologies Limited to Report Q1, 2024 Results on Jul 20, 2023 Quick Heal Technologies Limited announced that they will report Q1, 2024 results on Jul 20, 2023 Reported Earnings • Apr 19
Full year 2023 earnings released: EPS: ₹1.14 (vs ₹14.01 in FY 2022) Full year 2023 results: EPS: ₹1.14 (down from ₹14.01 in FY 2022). Revenue: ₹3.00b (down 12% from FY 2022). Net income: ₹64.0m (down 92% from FY 2022). Profit margin: 2.1% (down from 24% in FY 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Reported Earnings • Jan 25
Third quarter 2023 earnings released: ₹1.70 loss per share (vs ₹2.47 profit in 3Q 2022) Third quarter 2023 results: ₹1.70 loss per share (down from ₹2.47 profit in 3Q 2022). Revenue: ₹702.7m (down 12% from 3Q 2022). Net loss: ₹92.9m (down 165% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 8% per year. Ankündigung • Jan 17
Quick Heal Technologies Limited to Report Q3, 2023 Results on Jan 24, 2023 Quick Heal Technologies Limited announced that they will report Q3, 2023 results on Jan 24, 2023 Ankündigung • Nov 26
Quick Heal Technologies Limited Announces Resignation of Mehul Savla as Independent Director Quick Heal Technologies Limited informed that Mr. Mehul Savla, Independent Director of the Company, has tendered his resignation on November 25, 2022 being the date of receipt of such resignation letter by the company and which is effective from November 25, 2022. Mr. Mehul Savla, in his resignation letter, mentioned the reasons for his resignation is due to increased level of professional commitments at his end and this is impacting his ability to attend and participate in the Board meeting and committee meetings of the Company. Reported Earnings • Oct 21
Second quarter 2023 earnings released: EPS: ₹3.82 (vs ₹5.39 in 2Q 2022) Second quarter 2023 results: EPS: ₹3.82 (down from ₹5.39 in 2Q 2022). Revenue: ₹1.01b (down 2.7% from 2Q 2022). Net income: ₹221.6m (down 36% from 2Q 2022). Profit margin: 22% (down from 33% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Buying Opportunity • Sep 21
Now 21% undervalued Over the last 90 days, the stock is up 27%. The fair value is estimated to be ₹242, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 3.3%. Recent Insider Transactions • Sep 15
Insider recently sold ₹4.4m worth of stock On the 9th of September, Reetu Raina sold around 20k shares on-market at roughly ₹221 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months. Upcoming Dividend • Aug 11
Upcoming dividend of ₹4.50 per share Eligible shareholders must have bought the stock before 18 August 2022. Payment date: 26 September 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.6%). Ankündigung • Aug 03
Quick Heal Technologies Limited, Annual General Meeting, Aug 26, 2022 Quick Heal Technologies Limited, Annual General Meeting, Aug 26, 2022, at 15:30 Indian Standard Time. Agenda: To receive, consider and adopt he audited standalone financial statements of the Company for the financial year ended March 31, 2022 and the reports of the Board of Directors and the Auditors thereon; to receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended March 31, 2022 and the report of Auditors thereon; to declare Dividend on equity shares; to consider Appointment of Mr. Sanjay Katkar as a director liable to retire by rotation; to Approval for the Buyback of Equity Shares of the Company; and to consider other matters. Ankündigung • Aug 02
Quick Heal Technologies Limited Proposes Dividend for Year Ended March 31, 2022 Quick Heal Technologies Limited at AGM on to be held on August 26, 2022 proposed to declare a final dividend of INR 4.50 per equity share of face value INR 10 each for the year ended March 31, 2022. Ankündigung • Jul 22
Quick Heal Technologies Limited (BSE:539678) announces an Equity Buyback for 5,000,000 shares, for INR 1,500 million. Quick Heal Technologies Limited (BSE:539678) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 equity Shares, for INR 1500 million. The shares will be repurchased at a price of INR 300 per share. The share repurchase program is subject to approval of shareholders by way of a special resolution. Reported Earnings • Jul 22
First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.97 in 1Q 2022) First quarter 2023 results: EPS: ₹0.03 (down from ₹0.97 in 1Q 2022). Revenue: ₹642.8m (up 17% from 1Q 2022). Net income: ₹1.80m (down 97% from 1Q 2022). Profit margin: 0.3% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improved over the past week After last week's 22% share price gain to ₹200, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 64% over the past three years. Ankündigung • Jul 16
Quick Heal Technologies Limited to Report Q1, 2022 Results on Jul 21, 2022 Quick Heal Technologies Limited announced that they will report Q1, 2022 results on Jul 21, 2022 Ankündigung • Jun 12
Quick Heal Technologies Limited Announces Senior Management Changes Quick Heal Technologies Limited announced that Ms. Reetu Raina, Chief Human Resource Officer of the Company, has resigned from the services of the Company on account of personal reasons. The Company had accepted the resignation and placed on record, appreciation for the services rendered by her during her tenure as CHRO of the Company. Further to inform that Mr. Rahul Matta appointed as a Head - HR of the Company w.e.f June 10, 2022. The brief profile of Mr. Rahul Matta as below: He is an alumnus of IIM- Lucknow, over the past 17+ years of experience. He had worked in diversified roles in some industry leading companies like Sterlite, Genpact, Piramal Healhcare, Dr. Reddy's, Mahindra & Mahindra. Recent Insider Transactions • Jun 01
Head of Research & Development recently sold ₹2.9m worth of stock On the 25th of May, Bibhuti Kar sold around 16k shares on-market at roughly ₹179 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹14m more than they bought in the last 12 months. Ankündigung • May 08
Quick Heal Technologies Limited Recommends Final Dividend for the Year 2021-2022 Quick Heal Technologies Limited announced the board has recommended a final dividend of INR 4.5 per equity share of INR 10 each for the year 2021-22. Reported Earnings • May 07
Full year 2022 earnings released: EPS: ₹14.01 (vs ₹16.66 in FY 2021) Full year 2022 results: EPS: ₹14.01 (down from ₹16.66 in FY 2021). Revenue: ₹3.61b (up 8.4% from FY 2021). Net income: ₹831.9m (down 22% from FY 2021). Profit margin: 23% (down from 32% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Feb 16
Head of Research & Development recently sold ₹1.0m worth of stock On the 14th of February, Bibhuti Kar sold around 5k shares on-market at roughly ₹203 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.7m. Insiders have been net sellers, collectively disposing of ₹12m more than they bought in the last 12 months. Reported Earnings • Jan 25
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹2.47 (up from ₹2.10 in 3Q 2021). Revenue: ₹832.5m (up 19% from 3Q 2021). Net income: ₹142.9m (up 6.1% from 3Q 2021). Profit margin: 17% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year. Recent Insider Transactions • Dec 04
Insider recently sold ₹9.7m worth of stock On the 2nd of December, Nitin Kulkarni sold around 45k shares on-market at roughly ₹217 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months. Reported Earnings • Oct 28
Second quarter 2022 earnings released: EPS ₹5.39 (vs ₹4.49 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹1.04b (up 23% from 2Q 2021). Net income: ₹346.3m (up 20% from 2Q 2021). Profit margin: 33% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 3% per year. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment deteriorated over the past week After last week's 22% share price decline to ₹234, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Software industry in India. Total loss to shareholders of 6.5% over the past three years. Upcoming Dividend • Jul 22
Upcoming dividend of ₹4.00 per share Eligible shareholders must have bought the stock before 29 July 2021. Payment date: 05 September 2021. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.8%). Reported Earnings • Jul 14
Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.33b (up 16% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 32% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year. Recent Insider Transactions • Jun 02
Insider recently sold ₹1.6m worth of stock On the 31st of May, Manish Jain sold around 8k shares on-market at roughly ₹216 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹2.9m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improved over the past week After last week's 20% share price gain to ₹227, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 18x in the Software industry in India. Total loss to shareholders of 22% over the past three years. Ankündigung • May 16
Quick Heal Technologies Limited Recommends Final Dividend for the Year 2020-21 The Board of Quick Heal Technologies Limited has recommended a final dividend of INR 4 per equity share of INR 10 each for the year 2020-21. Reported Earnings • May 16
Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.57b (up 25% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 05
New 90-day high: ₹179 The company is up 11% from its price of ₹161 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 27% over the same period. Valuation Update With 7 Day Price Move • Mar 05
Investor sentiment improved over the past week After last week's 18% share price gain to ₹179, the stock is trading at a trailing P/E ratio of 15.3x, up from the previous P/E ratio of 13x. This compares to an average P/E of 18x in the Software industry in India. Total return to shareholders over the past three years is a loss of 27%. Reported Earnings • Feb 06
Third quarter 2021 earnings released: EPS ₹2.10 (vs ₹2.77 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹698.8m (up 6.3% from 3Q 2020). Net income: ₹134.6m (down 24% from 3Q 2020). Profit margin: 19% (down from 27% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Ankündigung • Jan 14
Quick Heal Technologies Limited (BSE:539678) entered into an agreement to acquire an additional unknown minority stake in L7 Defense Ltd. for $2 million. Quick Heal Technologies Limited (BSE:539678) entered into an agreement to acquire an additional unknown minority stake in L7 Defense Ltd. for $2 million on January 14, 2021. Under the terms, Quick Heal Technologies Limited will acquire 2328 ordinary shares of L7 Defense Ltd. The consideration will be paid in cash. L7 Defense Ltd. reported revenue of $0.156 million as of December 31, 2020. The transaction is expected to complete in the 1st week of February 2021. Reported Earnings • Nov 07
Second quarter 2021 earnings released: EPS ₹4.49 The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹902.4m (down 8.5% from 2Q 2020). Net income: ₹288.4m (down 22% from 2Q 2020). Profit margin: 32% (down from 37% in 2Q 2020). The decrease in margin was driven by lower revenue. Ankündigung • Oct 27
Quick Heal Technologies Limited Announces Board Appointments Quick Heal Technologies Limited appointed Mr. Sanjay Agrawal and Mr. Bibhuti Kar as Chief Product Officer and Head of Research and Development respectively. The expansion of the leadership team reinforces Quick Heal's commitment to accelerate product innovation and drive expansion of next-generation enterprise security solutions under the "Seqrite®" brand. In his role, Sanjay will be responsible for driving the overall product vision and strategy in line with market expectations. While Bibhuti will drive the company's development efforts leading a team of talented engineering professionals and security researchers. Sanjay is an entrepreneurial engineering and product leader with over two decades of experience and proven success in building cybersecurity products for the global markets. He has served many prestigious and high performing roles, including Vice President of Engineering Application and Security at ColorTokens and Director of Engineering at Cisco. Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry. An alumnus of IIT Kharagpur with a master's in ECE, he started his career with the Defense Research and Development Organization (DRDO) as a project assistant on missile communication systems. Post this, he held several prestigious roles in leading technology companies like Cisco, Bell Northern Research and Sophos. Is New 90 Day High Low • Oct 05
New 90-day high: ₹171 The company is up 47% from its price of ₹116 on 07 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 41% over the same period. 
